Unmet Needs in Darier's Disease from a Patient's Perspective: Lessons Learnt from the German Registry.
Humans
Registries
Darier Disease
/ therapy
Male
Female
Germany
Patient Satisfaction
Middle Aged
Aged
Adult
Treatment Outcome
Health Services Needs and Demand
Pemphigus, Benign Familial
/ diagnosis
Pruritus
/ etiology
Needs Assessment
Adrenal Cortex Hormones
/ therapeutic use
Retinoids
/ therapeutic use
Journal
Acta dermato-venereologica
ISSN: 1651-2057
Titre abrégé: Acta Derm Venereol
Pays: Sweden
ID NLM: 0370310
Informations de publication
Date de publication:
11 06 2024
11 06 2024
Historique:
received:
26
09
2023
accepted:
13
05
2024
medline:
11
6
2024
pubmed:
11
6
2024
entrez:
11
6
2024
Statut:
epublish
Résumé
The MDHHgermany registry was initiated to characterize the "real-life" situation of affected individuals with Darier's disease (DD; Morbus Darier, MD) and Hailey-Hailey disease (HH), including their treatment and healthcare. To gain deeper insights into medical care of patients with DD, various aspects such as demographics, subjective symptoms, patient satisfaction with medical care, past and current therapies were explored. Patients with diagnosed DD were included. Subjective symptoms such as itch, pain and burning sensation were assessed. Individual therapy goals were recorded and patients assessed previous/current therapies along with satisfaction of medical care and treatment. A total of 55 patients were recruited; 47 patients were eligible for the analysis. Pruritus was rated the most bothersome symptom. Some 42.6% had not received systemic treatment so far or systemic therapies were rated ineffective (32.6%). Most commonly oral retinoids were prescribed, followed by corticosteroids. Patient satisfaction with medical care and treatment proved to be mediocre. This "real-life" data show an alarming unmet need regarding patients' satisfaction with medical care and treatment, evidenced by the reported lack of disease control. Further studies and interventions are needed to improve the spectrum of available therapies. MDHHgermany provides a foundational platform for future clinical trials, epidemiological studies, and pathophysiological analyses.
Identifiants
pubmed: 38860622
doi: 10.2340/actadv.v104.19663
doi:
Substances chimiques
Adrenal Cortex Hormones
0
Retinoids
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM